HOME >> BIOLOGY >> NEWS
New diagnostic tool brings effective treatment closer to patients

Hamburg, Germany: Significant progress towards identifying the genetic make-up of individual tumours, hence allowing treatment choices to be made based on personalised information was announced at the 4th European Breast Cancer Conference, today. Dr. Alane Koki, Chief Scientific Officer of Ipsogen, a French biotechnology company, told a news briefing that, subject to the successful conclusion of ongoing validation studies, the Breast Cancer ProfileChipTM (BCPC) should be available for use in pathology laboratories by Summer 2004.

One of the biggest obstacles to effective breast cancer treatment and management is the amount of genetic variability between patients. The BCPC uses microarray technology* to look at the individual molecular characteristics of each patient's tumour. "Understanding differences in gene expression can help both patients and clinicians to decide what treatment would be most effective and appropriate with a personalised approach", said Dr. Koki.

Looking at the 'genetic signature' of a tumour can provide crucial information to contribute to the choice of first-line treatment. It can also avoid over-treatment or prolonged treatment with ineffective drugs and the associated side effects. The use of microarrays will be able to predict relapse or metastatic disease in patients treated by the current standard of care, therefore sparing selected patients from chemotherapy or closer monitoring and/or dose intensification in patients at high risk. The information provided by this new tool should lead to better management of breast cancer, improve the quality of patient life, as well as reduce the costs of treatment to health services.

"To our knowledge, the BCPC will be the first microarray diagnostic tool available to local pathology laboratories, thus bringing the technology closer to the patient", said Dr. Koki. Although a few similar diagnostic methods are already available, to date they have involved sen
'"/>

Contact: Mary Rice
mary.rice@blueprintpartners.be
49-40-3569-3625
Federation of European Cancer Societies
17-Mar-2004


Page: 1 2

Related biology news :

1. Yale digital diagnostic technology is basis of new company, HistoRx Inc.
2. New diagnostic technology helps justify earlier cataract surgery
3. Nanoparticle probes are destined for major new role in medical diagnostics and drug delivery
4. Smallpox in 50-year-old tissues detected by integrated diagnostics approach
5. Worlds leading mad cow diagnostic company, responds to USDAs additional BSE protection measures
6. Advances in prosthetic, orthopedic, and audiologic diagnostic tools
7. FDA clears for market new diagnostic test for lupus
8. New method of DNA testing promises to transform medical diagnostics
9. Leading lab expert to update medical community on diagnostic testing for thyroid function
10. New Arizona State center brings science to policy on issues of water resources and urban growth
11. From science fiction to reality: Nanomedicine brings fresh hope to the medical world

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2019)... , ... February 20, 2019 , ... ... announced plans today to expand the company’s footprint in Frederick, MD after a ... have used RoosterBio’s adult human mesenchymal stem/stromal cell (hMSCs) products to streamline their ...
(Date:2/22/2019)... ... , ... Clean label food is not just another passing trend in the ... is quite common to spot consumers running their index finger across the back of ... label scrutiny. , More than ever, meat and poultry producers are working diligently ...
(Date:2/22/2019)... ... February 21, 2019 , ... ... implanted SpineFrontier’s SacroFuse system in conjunction with NanoFUSE’s Orthobiologic ... case represents the first time that either SacroFuse or NanoFUSE have been used ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... ... This free webinar will review strategies for data management in modular and adaptive ... build times by up to 30 percent, reducing cost while increasing quality, achieving clinical site ... need to migrate data – reducing risk and impact on trial success, trial teams, and ...
(Date:3/14/2019)... ... March 14, 2019 , ... EyeCRO ... Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical ... as the fifth institution in Oklahoma to receive this prestigious endorsement. The ...
(Date:3/14/2019)... ... March 13, 2019 , ... The International Society for ... taking place in Brussels, Belgium on 25–26 September 2019. This event is a ... innovative approaches. , “Biopharmaceuticals have become a main pillar in the pharmaceutical ...
(Date:3/11/2019)... ... March 11, 2019 , ... USDM Life Sciences and Generis ... with built in GxP compliance for the life sciences industry. USDM Cloud Assurance ... continuous compliance for Generis’ flagship product, CARA. , Presentation One:, ...
Breaking Biology Technology:
Cached News: